These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 15879369)

  • 1. Pharmacogenetics and ethnically targeted therapies.
    Rahemtulla T; Bhopal R
    BMJ; 2005 May; 330(7499):1036-7. PubMed ID: 15879369
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacogenetics and ethnically targeted therapies: racial drugs need to be put in context.
    Kahn JD
    BMJ; 2005 Jun; 330(7506):1508; author reply 1508. PubMed ID: 15976430
    [No Abstract]   [Full Text] [Related]  

  • 3. Medicine. Race and reification in science.
    Duster T
    Science; 2005 Feb; 307(5712):1050-1. PubMed ID: 15718453
    [No Abstract]   [Full Text] [Related]  

  • 4. Genotyping the future: scientists' expectations about race/ ethnicity after BiDil.
    Tutton R; Smart A; Martin PA; Ashcroft R; Ellison GT
    J Law Med Ethics; 2008; 36(3):464-70. PubMed ID: 18840237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. "Racially-tailored" medicine unraveled.
    Hoffman S
    Am Univ Law Rev; 2005 Dec; 55(2):395-452. PubMed ID: 16619445
    [No Abstract]   [Full Text] [Related]  

  • 6. Race as a proxy for drug response: the dangers and challenges of ethnic drugs.
    Bowser R
    De Paul Law Rev; 2004; 53(3):1111-26. PubMed ID: 16211761
    [No Abstract]   [Full Text] [Related]  

  • 7. The case of BiDil: a policy commentary on race and genetics.
    Carlson RJ
    Health Aff (Millwood); 2005; Suppl Web Exclusives():W5-464-8. PubMed ID: 16219648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hydralazine and nitrates: beyond race and ethnicity.
    Ghali JK
    J Card Fail; 2007 Apr; 13(3):238. PubMed ID: 17448423
    [No Abstract]   [Full Text] [Related]  

  • 9. Exploiting race in drug development: BiDil's interim model of pharmacogenomics.
    Kahn J
    Soc Stud Sci; 2008 Oct; 38(5):737-58. PubMed ID: 19227819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BiDil: race medicine or race marketing?
    Sankar P; Kahn J
    Health Aff (Millwood); 2005; Suppl Web Exclusives():W5-455-63. PubMed ID: 16219647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Question: does isosorbide dinitrate/hydralazine therapy benefit systolic heart failure patients with renal insufficiency?
    Pan L; Payne J; Clark M
    J Okla State Med Assoc; 2011 Feb; 104(2):49-50. PubMed ID: 21815321
    [No Abstract]   [Full Text] [Related]  

  • 12. Effect of enalapril, hydralazine plus isosorbide dinitrate, and prazosin on hospitalization in patients with chronic congestive heart failure. The V-HeFT VA Cooperative Studies Group.
    Loeb HS; Johnson G; Henrick A; Smith R; Wilson J; Cremo R; Cohn JN
    Circulation; 1993 Jun; 87(6 Suppl):VI78-87. PubMed ID: 8500244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study.
    Cohn JN; Archibald DG; Ziesche S; Franciosa JA; Harston WE; Tristani FE; Dunkman WB; Jacobs W; Francis GS; Flohr KH
    N Engl J Med; 1986 Jun; 314(24):1547-52. PubMed ID: 3520315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enalapril decreases prevalence of ventricular tachycardia in patients with chronic congestive heart failure. The V-HeFT II VA Cooperative Studies Group.
    Fletcher RD; Cintron GB; Johnson G; Orndorff J; Carson P; Cohn JN
    Circulation; 1993 Jun; 87(6 Suppl):VI49-55. PubMed ID: 8500239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma norepinephrine, plasma renin activity, and congestive heart failure. Relations to survival and the effects of therapy in V-HeFT II. The V-HeFT VA Cooperative Studies Group.
    Francis GS; Cohn JN; Johnson G; Rector TS; Goldman S; Simon A
    Circulation; 1993 Jun; 87(6 Suppl):VI40-8. PubMed ID: 8500238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Veterans Administration Cooperative Study on Vasodilator Therapy of Heart Failure: influence of prerandomization variables on the reduction of mortality by treatment with hydralazine and isosorbide dinitrate.
    Cohn JN; Archibald DG; Francis GS; Ziesche S; Franciosa JA; Harston WE; Tristani FE; Dunkman WB; Jacobs W; Flohr KH
    Circulation; 1987 May; 75(5 Pt 2):IV49-54. PubMed ID: 3552302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment of advanced heart failure with hydralazine and isosorbide dinitrate (author's transl)].
    Lanas F; Salvatici R; Opazo JA; Saavedra J; Iturriaga J
    Rev Med Chil; 1979 Oct; 107(10):926-30. PubMed ID: 550229
    [No Abstract]   [Full Text] [Related]  

  • 18. On the selling of pharmaceuticals.
    DeMaria AN
    J Am Coll Cardiol; 2005 Nov; 46(10):1953-4. PubMed ID: 16286185
    [No Abstract]   [Full Text] [Related]  

  • 19. Seeking the value of pharmacogenetics in cardiovascular care.
    Otrompke J
    Biotechnol Healthc; 2007 Feb; 4(1):61-2. PubMed ID: 23397416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The potential and limitations of personalized medicine in the doctor-patient relationship.
    Hapgood R
    Pharmacogenomics; 2003 Nov; 4(6):685-7. PubMed ID: 14596632
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.